The efficacy advantage of evolocumab (AMG 145) dosed at 140 mg every 2 weeks versus 420 mg every 4 weeks in patients with hypercholesterolemia: Evidence from a meta-analysis-Reference-Cited by-同舟云学术

The efficacy advantage of evolocumab (AMG 145) dosed at 140 mg every 2 weeks versus 420 mg every 4 weeks in patients with hypercholesterolemia: Evidence from a meta-analysis

Published:2017-03 Issue: Volume:38 Page:52-60
ISSN:0953-6205
Container-title:European Journal of Internal Medicine
language:en
Short-container-title:European Journal of Internal Medicine

Author:

He Xiao-Xiao,Zhang Rong,Zuo Pei-Yuan,Liu Yu-Wei,Zha Xiang-Nan,Shan Sheng-Shuai,Liu Cheng-Yun

Publisher

Elsevier BV

Subject

Internal Medicine

Reference35 articles.

1. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report;Third Report of the National Cholesterol Education Program (NCEP);Circulation,2002

2. Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: findings from the EUROASPIRE III survey;Reiner;Atherosclerosis,2013

3. Proprotein convertases in health and disease;Artenstein;N Engl J Med,2011

4. PCSK9: a convertase that coordinates LDL catabolism;Horton;J Lipid Res,2009

5. Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis;Qian;J Lipid Res,2007

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Efficacy of Tafolecimab in Chinese Patients with Hypercholesterolemia: A Systematic Review and Meta-analysis;American Journal of Cardiovascular Drugs;2024-06-24

2. A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia;BioMed Research International;2021-10-31

3. Three Musketeers for Lowering Cholesterol: Statins, Ezetimibe and Evolocumab;Current Medicinal Chemistry;2021-04-01

4. PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma;Experimental Hematology & Oncology;2021-03-31

5. Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review;Expert Review of Clinical Pharmacology;2020-07-02